These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1061 related items for PubMed ID: 18463509

  • 1. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA.
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [Abstract] [Full Text] [Related]

  • 2. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A.
    Retina; 2006 May; 26(9):988-93. PubMed ID: 17151484
    [Abstract] [Full Text] [Related]

  • 3. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU.
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [Abstract] [Full Text] [Related]

  • 5. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA.
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [Abstract] [Full Text] [Related]

  • 6. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
    Spaide RF, Sorenson J, Maranan L.
    Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Aug; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ, Couch SM, McCannel CA, Edwards AO.
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I.
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [Abstract] [Full Text] [Related]

  • 17. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Sep; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L, Leys A.
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.